Building a community-based cooperative e-learning platform for Taiwanese tribal elders
In: Gerontechnology: international journal on the fundamental aspects of technology to serve the ageing society, Band 13, Heft 2
ISSN: 1569-111X
9 Ergebnisse
Sortierung:
In: Gerontechnology: international journal on the fundamental aspects of technology to serve the ageing society, Band 13, Heft 2
ISSN: 1569-111X
In: Waste management: international journal of integrated waste management, science and technology, Band 26, Heft 5, S. 509-515
ISSN: 1879-2456
In: The Economic Journal, Band 82, Heft 325, S. 217
In: Journal of the International AIDS Society, Band 11, Heft Suppl 1, S. P207
ISSN: 1758-2652
In: Gerontechnology: international journal on the fundamental aspects of technology to serve the ageing society, Band 13, Heft 2
ISSN: 1569-111X
In: Journal of the International AIDS Society, Band 15, Heft S4, S. 1-2
ISSN: 1758-2652
Purpose of studySafety and efficacy of raltegravir (RAL) in patients (pts) with HIV and hepatitis B and/or C (HBV/HCV) co‐infection were evaluated in a double‐blind fashion for 5 years in STARTMRK and 3 years in BENCHMRK‐1&2.MethodsIn STARTMRK, treatment‐naïve pts received RAL 400 mg bid or efavirenz (EFV) 600 mg qhs, both with tenofovir+emtricitabine (TDF/FTC), for up to 240 weeks. In BENCHMRK‐1&2, highly treatment‐experienced pts with multidrug‐resistant virus and failing other therapies received double‐blind RAL 400 mg bid or placebo, both with optimized background therapy (OBT), for up to 156 weeks. Pts with stable chronic HBV/HCV could enroll if baseline AST and ALT were=5×upper limit of normal.Summary of results743 pts received RAL and 519 received comparator. Hepatitis co‐infection was present in 6% (34/563) of treatment‐naïve pts (HBV=4%, HCV=2%, HBV+HCV=0.2%) and 16% (114/699) of treatment‐experienced pts (HBV=6%, HCV=9%, HBV+HCV=1%). Safety and efficacy results at the end of double‐blind treatment are shown by study, treatment group and co‐infection status. Liver enzyme elevations were more common in pts with HIV+HBV/HCV co‐infection than in pts with HIV infection alone, in the RAL and control groups. Most liver enzyme changes occurred in the first 48 weeks of treatment, with minimal further increases (data not shown).ConclusionRAL was efficacious and generally well tolerated for up to 5 years in pts with HIV+HBV/HCV co‐infection. The majority of grade 3 and grade 4 liver enzyme elevations occurred during the first year of treatment and were more common among co‐infected pts than among HIV mono‐infected pts, irrespective of treatment group.
STARTMRK (treatment‐naive), 240 weeks
BENCHMRK (treatment‐experienced), 156 weeks
RAL+TDF/FTC
EFV+TDF/FTC
RAL+OBT
Placebo+OBT
HBV or HCV positive N=18 %
HBV … HCV negative N=263%
HBV or HCV positive N=16%
HBV … HCV negative N=266%
HBV or HCV positive N=77 (PYR=182) % (rate/100 PYR)†
HBV … HCV negative N=385 (PYR=869) % (rate/100 PYR)†
HBV or HCV positive N=37 (PYR=43) % (rate/100 PYR)†
HBV … HCV negative N=200 (PYR=280) % (rate/100 PYR)†
Aspartate aminotransferase (AST) increased
Grade 3‡
5.6
4.6
0
3.0
9.1 (3.8)
3.4 (1.5)
2.7 (2.3)
3.0 (2.1)
Grade 4‡
5.6
0.8
6.3
0
2.6 (1.1)
0.3 (0.1)
0
1.5 (1.1)
Alanine aminotransferase (ALT) increased
Grade 3‡
0
1.9
6.3
1.9
10.4 (4.4)
3.6 (1.6)
8.1 (7.0)
1.5 (1.1)
Grade 4‡
5.6
1.5
6.3
0.4
3.9 (1.6)
0.8 (0.3)
0
2.0 (1.4)
Bilirubin increased
Grade 3‡
0
0.8
0
0
3.9 (1.6)
2.9 (1.3)
5.4 (4.7)
2.0 (1.4)
Grade 4‡
0
0.4
0
0
1.3 (0.5)
0.8 (0.3)
0
0
Clinical adverse events, %
Any clinical AE
94.4
96.6
93.8
98.1
93.6
94.0
86.5
90.5
Discontinued
5.6
4.9
6.3
8.3
3.8
4.7
2.7
6.0
Hepatobiliary AE
5.6
5.7
0
3.4
7.8
4.2
5.4
5.5
Discontinued
5.6
0.4
0
0.4
0
0.5
0
0.4
Efficacy: % with HIV RNA<50 copies/mL (Observed Failure approach)
90.9
89.1
91.7
80.0
62.3
57.9
14.7
26.3
Exposure‐adjusted rates per 100 patient‐years at risk (PYR); shown for BENCHMRK studies only, due to longer exposure in RAL group.
Division of AIDS toxicity criteria.
In: Environmental science and pollution research: ESPR, Band 19, Heft 7, S. 2515-2527
ISSN: 1614-7499
In: Journal of the International AIDS Society, Band 13, Heft S4
ISSN: 1758-2652
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MoST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; SENESCYT (Ecuador) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBE DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; BUAP (Mexico) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; LNS (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; RAEP (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; PCTI (Spain) ; FEDER (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie Curie programme (European Union) ; European Research Council and Horizon Grant (European Union) ; Leventis Foundation ; A. P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS programme of the Foundation for Polish Science ; European Union ; Regional Development Fund ; Mobility Plus programme of the Ministry of Science and Higher Education (Poland) ; National Science Center (Poland) ; National Priorities Research Program by Qatar National Research Fund ; Programa Clarin-COFUND del Principado de Asturias ; Thalis programme - EU-ESF ; Aristeia programme - EU-ESF ; Greek NSRF ; Rachadapisek Sompot Fund for Postdoctoral Fellowship (Thailand) ; Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; European Research Council and Horizon Grant (European Union): 675440 ; National Science Center (Poland): Harmonia 2014/14/M/ST2/00428 ; National Science Center (Poland): Opus 2014/13/B/ST2/02543 ; National Science Center (Poland): 2014/15/B/ST2/03998 ; National Science Center (Poland): 2015/19/B/ST2/02861 ; National Science Center (Poland): Sonata-his 2012/07/E/ST2/01406 ; Welch Foundation: C-1845 ; A measurement of the differential cross sections for a W boson produced in association with jets in the muon decay channel is presented. The measurement is based on 13 TeV proton-proton collision data corresponding to an integrated luminosity of 2.2 fb(-1), recorded by the CMS detector at the LHC. The cross sections are reported as functions of jet multiplicity, jet transverse momentum pT, jet rapidity, the scalar pT sum of the jets, and angular correlations between the muon and each jet for different jet multiplicities. The measured cross sections are in agreement with predictions that include multileg leading-order (LO) and next-to-LO matrix element calculations interfaced with parton showers, as well as a next-to-next-to-LO calculation for the W boson and one jet production.
BASE